Las Vegas, NV - 
(NewMediaWire) - November 17, 2022 - BioAdaptives, Inc. (OTC BDPT) , in response to increasing demand for anti-aging supplements, the Company offers Cell Rejuven™, an advanced, plant-based formula designed to combat chronic inflammation, oxidative stress, foster immune system balance and promote stem cell activity. These beneficial effects are particularly important for the U.S. Senior population, those 65 and older, estimated to be 54 million in 2019. The global market for Anti-Aging Products estimated at US $34.2 Billion in the year 2020, is projected to reach a revised size of US $47.8 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027.
The Company developed and test marketed this formulation, based on Traditional Chinese Medicine and Ayurvedic Culture, in response to the strong demand for a premium, vegan friendly product that promotes anti-aging and rejuvenating effects.
Edward Jacobs, M.D., Bioadaptives CEO, states, “Cell Rejuven™, an all-natural, gluten-free, non- GMO supplement formulation, is designed to achieve and maintain rejuvenating effects not only for the skin, hair and nails but also for all parts of the body including the brain, heart, lungs and other vital organs. Cell Rejuven contains spirulina and other all natural ingredients that maximize gastrointestinal uptake and bioavailability of nutrients, including essential amino acids, vitamins, minerals and fatty acids with Omegas. The Anti-Viral, Anti-Bacterial and Anti-Fungal features of Cell Rejuven combat external threats while its Anti-inflammatory and Antioxidant activity help to balance the immune system and decrease damage from oxidative stress. Importantly, the stimulation of primitive cells, including young stem cells and their derivatives is critical for rapid recovery and replacement of aged and damaged cells. The superior quality ingredients are selected for their individual beneficial effects and for their expected synergistic features.”
About BioAdaptives, Inc.
BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses.
Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.”
Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Contact:
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com
View the original release on www.newmediawire.com
